Latest Information Update: 15 Sep 2004
At a glance
- Originator Aventis
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Nov 2003 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
- 07 Nov 1997 No-Development-Reported for Thrombosis in Germany (Unknown route)
- 24 Oct 1994 Preclinical development for Thrombosis in Germany (Unknown route)